2025
Prospective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems
Kwon J, Tanner W, Kong Y, Wade M, Bitler C, Chiavegato M, Pettigrew M. Prospective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems. MSphere 2025, 10: e00738-24. PMID: 39950811, PMCID: PMC11934311, DOI: 10.1128/msphere.00738-24.Peer-Reviewed Original ResearchConceptsFarm management strategiesPost-weaningGrain dietGrass-fedFeed additivesPre-harvestProduction systemsResistance genesCattle production systemsPre-weaning periodFarm management practicesAbundance of antibiotic resistance genesBacterial communitiesFecal swab samplesPasture-raisedDiversity of ARGsGrain-fedBeef cattlePre-weaningMonths of ageGrowth promotionCattleBacterial community changesFood animalsFecal swabs
2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalenceTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAdministration, CutaneousAnti-Bacterial AgentsClindamycinDrug Resistance, BacterialHumansTreatment OutcomeConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibioticsMtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
Boshoff H, Young K, Ahn Y, Yadav V, Crowley B, Yang L, Su J, Oh S, Arora K, Andrews J, Manikkam M, Sutphin M, Smith A, Weiner D, Piazza M, Fleegle J, Gomez F, Dayao E, Prideaux B, Zimmerman M, Kaya F, Sarathy J, Tan V, Via L, Tschirret-Guth R, Lenaerts A, Robertson G, Dartois V, Olsen D, Barry C. Mtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS Infectious Diseases 2024, 10: 1679-1695. PMID: 38581700, DOI: 10.1021/acsinfecdis.4c00025.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntitubercular AgentsDrug Resistance, BacterialHumansLinezolidMiceMicrobial Sensitivity TestsMitochondriaMycobacterium tuberculosisOxazolidinonesProdrugsConceptsLinezolid-resistant mutantsDrug-resistant patientsAntitubercular activityN-acetyl metaboliteOxazolidinone prodrugMechanism of actionC3HeB/FeJ miceAntimycobacterial activityN-acetyl transferaseSusceptible to inhibitionCross-resistanceOxazolidinoneCompoundsMoleculesMammalian metabolismN-acetyltransferaseProdrugToxicityMoietyProtein synthesisLinezolidC3HeB/FeJCaseumPatientsLiving cells
2023
Genomic analysis of Shigella isolates from Lebanon reveals marked genetic diversity and antimicrobial resistance
Yassine I, Rafei R, de la Gandara M, Osman M, Fabre L, Dabboussi F, Hamze M, Weill F. Genomic analysis of Shigella isolates from Lebanon reveals marked genetic diversity and antimicrobial resistance. Microbial Genomics 2023, 9: 001157. PMID: 38100171, PMCID: PMC10763507, DOI: 10.1099/mgen.0.001157.Peer-Reviewed Original ResearchConceptsExtended-spectrum beta-lactamase genesThird-generation cephalosporinsMultidrug resistance phenotypeBeta-lactamase genesAntimicrobial resistance determinantsPrevalent serogroupsClinical isolatesQuinolone resistanceDNA gyrase genesAntimicrobial resistanceResistance determinantsCTXResistance phenotypeAmino acid substitutionsGyrase genesIsolatesNorth LebanonFirst studyAcid substitutionsPoint mutationsGenomic analysisCephalosporinsThe Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group
Harris A, Souli M, Pettigrew M, Group F. The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases 2023, 77: s331-s335. PMID: 37843116, PMCID: PMC10578050, DOI: 10.1093/cid/ciad532.Peer-Reviewed Original ResearchThe Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactRapid antimicrobial resistance detection methods for bloodstream infection in solid organ transplantation: Proposed clinical guidance, unmet needs, and future directions
Turbett S, Banach D, Bard J, Gandhi R, Letourneau A, Azar M. Rapid antimicrobial resistance detection methods for bloodstream infection in solid organ transplantation: Proposed clinical guidance, unmet needs, and future directions. Transplant Infectious Disease 2023, 25: e14113. PMID: 37594214, DOI: 10.1111/tid.14113.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Bacterial AgentsAnti-Infective AgentsCommunicable DiseasesDrug Resistance, BacterialHumansOrgan TransplantationSepsisTransplant RecipientsConceptsUnmet needSolid organ transplant recipientsOrgan transplant recipientsSolid organ transplantationTransplant infectious diseasesEffective antimicrobial therapyPositive blood culturesFast institutionSOT recipientsTransplant recipientsDiagnostic stewardshipBloodstream infectionsAntimicrobial therapyBlood culturesClinical guidanceOrgan transplantationConsensus conferenceClinical practiceInfectious diseasesClinical microbiologyAmerican SocietyTransplantationResistance detectionBacterial resistanceRecipientsFighting the hidden pandemic of antimicrobial resistance in paediatrics: recommendations from the International Pediatric Association
Pana Z, El-Shabrawi M, Sultan M, Murray T, Alam A, Yewale V, Dharmapalan D, Klein J, Haddad J, Thacker N, Pulungan A, Hadjipanayis A. Fighting the hidden pandemic of antimicrobial resistance in paediatrics: recommendations from the International Pediatric Association. BMJ Paediatrics Open 2023, 7: e002084. PMID: 37500294, PMCID: PMC10387713, DOI: 10.1136/bmjpo-2023-002084.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChildDrug Resistance, BacterialHumansMicrobial Sensitivity TestsPandemicsOpen-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapyMycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition
van der Heijden Y, Maruri F, Blackman A, Morrison R, Guo Y, Sterling T. Mycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition. The Journal Of Infectious Diseases 2023, 228: 469-478. PMID: 37079382, PMCID: PMC10428193, DOI: 10.1093/infdis/jiad112.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialFluoroquinolonesGene ExpressionMicrobial Sensitivity TestsMycobacterium tuberculosisOfloxacinVerapamilConceptsExpression quantitative trait lociExpression quantitative trait loci analysisOfloxacin minimum inhibitory concentrationMinimum inhibitory concentrationWhole-genome sequencingRNA-seqEfflux pump inhibitionMTB isolatesGene expressionAllele frequency differencesQuantitative trait lociFluoroquinolone resistanceFold changePump inhibitionGenome sequenceFluoroquinolone-resistant Mycobacterium tuberculosisTrait lociRegulated genesAntituberculosis drug resistanceRNA sequencingEfflux pumpsEfflux pump inhibitor verapamilIncreased gene expressionGenesInhibitory concentration
2022
Antimicrobial resistance trends among canine Escherichia coli isolated at a New York veterinary diagnostic laboratory between 2007 and 2020
Osman M, Albarracin B, Altier C, Gröhn Y, Cazer C. Antimicrobial resistance trends among canine Escherichia coli isolated at a New York veterinary diagnostic laboratory between 2007 and 2020. Preventive Veterinary Medicine 2022, 208: 105767. PMID: 36181749, PMCID: PMC9703301, DOI: 10.1016/j.prevetmed.2022.105767.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Bacterial AgentsAnti-Infective AgentsCephalosporinsDog DiseasesDogsDrug Resistance, BacterialEnrofloxacinEscherichia coliEscherichia coli InfectionsFluoroquinolonesGentamicinsMicrobial Sensitivity TestsNew YorkRetrospective StudiesTrimethoprim, Sulfamethoxazole Drug CombinationConceptsTrimethoprim-sulfamethoxazole resistanceBody sitesGood first-line choiceCanine urinary tract infectionsResistant isolatesResistance trendsLaboratory Standards Institute breakpointsMultivariable logistic regression modelAntimicrobial resistance surveillance studyUrinary tract infectionDrug-resistant Escherichia coliFirst-line choiceAvailable clinical dataDrug-resistant E. coliAntimicrobial susceptibility patternsRetrospective study designUse of fluoroquinolonesE. coli infectionAntimicrobial resistance trendsResistance surveillance studiesClinical E. coliLogistic regression modelsEnrofloxacin-resistant isolatesSurvival analysis dataMIC trendsHigh rates of macrolide and fluoroquinolone resistance in human campylobacteriosis in the Middle East and North Africa
Dabbousi A, Osman M, Dabboussi F, Hamze M. High rates of macrolide and fluoroquinolone resistance in human campylobacteriosis in the Middle East and North Africa. Future Microbiology 2022, 17: 957-967. PMID: 35796073, DOI: 10.2217/fmb-2021-0302.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsCampylobacter InfectionsCampylobacter jejuniDrug Resistance, BacterialFluoroquinolonesHumansIntraabdominal InfectionsLebanonMacrolidesMicrobial Sensitivity TestsConceptsHuman campylobacteriosisRoutine stool cultureBacterial gastrointestinal infectionsClinical laboratoriesIncidence of campylobacteriosisPaucity of dataMain causative agentStool culturesGastrointestinal infectionsDiarrheal patientsMicrobiological diagnosisClinical importanceFluoroquinolone resistanceInfection prevalenceAntimicrobial resistanceZoonotic diseaseCausative agentCampylobacteriosisHigh rateAlarming ratePatientsCritical needEpidemiologyInfectionPrevalenceLetter to the Editor: First Report of the Detection of the Plasmid-Borne Colistin Resistance Gene, mcr-1.26, in Multidrug-Resistant Escherichia coli Isolated from a Domesticated Pigeon
Kassem I, Assi A, Osman M, Mann D, Li S, Deng X. Letter to the Editor: First Report of the Detection of the Plasmid-Borne Colistin Resistance Gene, mcr-1.26, in Multidrug-Resistant Escherichia coli Isolated from a Domesticated Pigeon. Microbial Drug Resistance 2022, 28: 821-823. PMID: 35639443, DOI: 10.1089/mdr.2021.0359.Peer-Reviewed Original ResearchMachine-learning approaches prevent post-treatment resistance-gaining bacterial recurrences
Osman M, Mahieu R, Eveillard M. Machine-learning approaches prevent post-treatment resistance-gaining bacterial recurrences. Trends In Microbiology 2022, 30: 612-614. PMID: 35599112, DOI: 10.1016/j.tim.2022.05.006.Peer-Reviewed Original ResearchEstimating the impact of health systems factors on antimicrobial resistance in priority pathogens
Awasthi R, Rakholia V, Agrawal S, Dhingra L, Nagori A, Kaur H, Sethi T. Estimating the impact of health systems factors on antimicrobial resistance in priority pathogens. Journal Of Global Antimicrobial Resistance 2022, 30: 133-142. PMID: 35533985, DOI: 10.1016/j.jgar.2022.04.021.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBayes TheoremDrug Resistance, BacterialHumansStaphylococcal InfectionsStaphylococcus aureusConceptsGlobal Burden of DiseaseHealth system factorsAntimicrobial resistanceReducing antimicrobial resistanceSystemic factorsBurden of diseaseHigh-income countriesResistance to ceftarolineDeterminants of antimicrobial resistanceDisease burden variablesObstetric careAntimicrobial resistance dataCausal machine learningQuality of governanceGlobal antimicrobial resistanceBurden variablesHealth approachBayesian decision networkGlobal burdenDesign interventionsAntibiotic susceptibilityKnowledge discovery approachGovernment effectivenessPriority pathogensGeopolitical factorsRapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections
Chung H, Merakou C, Schaefers M, Flett K, Martini S, Lu R, Blumenthal J, Webster S, Cross A, Al Ahmar R, Halpin E, Anderson M, Moore N, Snesrud E, Yu H, Goldberg J, O’Toole G, McGann P, Stam J, Hinkle M, McAdam A, Kishony R, Priebe G. Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections. Nature Communications 2022, 13: 1231. PMID: 35264582, PMCID: PMC8907320, DOI: 10.1038/s41467-022-28188-w.Peer-Reviewed Original ResearchConceptsAntibiotic resistance mutationsResistance mutationsLong-read sequencingEvolution of antibiotic resistanceSputum samplesRespiratory infectionsCulture-based methodsLow-frequency resistance mutationsColonization bottlenecksEarly stages of infectionDays of therapyAcute bacterial infectionBacterial respiratory infectionsMechanically ventilated patientsGenomic surveillanceResistance phenotypeStages of infectionAntibiotic resistanceIn vivo frequencyAntibiotic therapyAntibiotic changeMutationsAntibiotic switchTherapy choiceIndividual patientsA global snapshot on the prevalent macrolide-resistant emm types of Group A Streptococcus worldwide, their phenotypes and their resistance marker genotypes during the last two decades: A systematic review
Rafei R, Al Iaali R, Osman M, Dabboussi F, Hamze M. A global snapshot on the prevalent macrolide-resistant emm types of Group A Streptococcus worldwide, their phenotypes and their resistance marker genotypes during the last two decades: A systematic review. Infection Genetics And Evolution 2022, 99: 105258. PMID: 35219865, DOI: 10.1016/j.meegid.2022.105258.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBiomarkersDrug Resistance, BacterialGenotypeHumansMacrolidesPhenotypeStreptococcal InfectionsStreptococcus pyogenesConceptsEmm typesMacrolide resistance phenotypeEmm clustersMacrolide resistanceSystematic reviewPeculiar epidemiological featuresPresent systematic reviewEmm pattern AGroup A StreptococcusResistance phenotypeClinical presentationMiddle-income countriesEpidemiological featuresHigh-income countriesExclusion criteriaMacrolide susceptibilityA StreptococcusEpidemiological surveillanceSustained surveillancePattern EPattern AIncome countriesPhenotypeSurveillanceEpidemiological dynamicsGenome sequence of a multidrug-resistant Campylobacter coli strain isolated from a newborn with severe diarrhea in Lebanon
Halimeh F, Rafei R, Diene S, Osman M, Kassem I, Jamal Akoum R, Moudani W, Hamze M, Rolain J. Genome sequence of a multidrug-resistant Campylobacter coli strain isolated from a newborn with severe diarrhea in Lebanon. Folia Microbiologica 2022, 67: 319-328. PMID: 34997523, DOI: 10.1007/s12223-021-00921-w.Peer-Reviewed Original ResearchConceptsCampylobacter coli strainsSevere diarrheaST-828 complexC. coli isolatesBurden of CampylobacterBeta-lactam resistanceNew sequence typesSequencing analysisEpidemiological backgroundColi isolatesWhole-genome sequencing analysisAminoglycoside resistanceC. coliColi strainsAntimicrobial resistanceBlaOXA-61Virulence determinantsDisk diffusionMLST analysisWGS analysisDiarrheaNewbornsPTet plasmidAntimicrobial susceptibility phenotypesSusceptibility phenotypevCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding
Tran VN, Shams A, Ascioglu S, Martinecz A, Liang J, Clarelli F, Mostowy R, Cohen T, Abel zur Wiesch P. vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding. BMC Bioinformatics 2022, 23: 22. PMID: 34991453, PMCID: PMC8734216, DOI: 10.1186/s12859-021-04536-3.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacteriaComputer SimulationDrug Resistance, BacterialModels, BiologicalConceptsOwn computational model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply